About Haelixa
Haelixa is a company based in Zurich (Switzerland) founded in 2015 was acquired by Clariant in September 2018. Haelixa has raised $2.49 million across 5 funding rounds from investors including Clariant, Zurcher Kantonalbank and European Union. Haelixa offers products and services including DNA Marking Technology. Haelixa operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Zurich, Switzerland
-
Sectors
HealthcareRetail Energy & Utilities
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Haelixa
Haelixa offers a comprehensive portfolio of products and services, including DNA Marking Technology.
Uses DNA to track and verify material origins in supply chains.
People of Haelixa
Unlock access to complete
Funding Insights of Haelixa
Haelixa has successfully raised a total of $2.49M across 5 strategic funding rounds. The most recent funding activity was a Seed round of $2.37 million completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Seed — $2.4M
-
First Round
First Round
(09 Jan 2017)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2026 | Amount | Seed - Haelixa | Valuation | Verve Ventures , Zurcher Kantonalbank | |
| Sep, 2019 | Amount | Seed - Haelixa | Valuation | Verve Ventures | |
| Sep, 2017 | Amount | Grant - Haelixa | Valuation |
investors |
|
Investors in Haelixa
Haelixa has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Clariant, Zurcher Kantonalbank and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on science and tech-driven startups
|
Founded Year | Domain | Location | |
|
University backed startup accelerator
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
Investments & Acquisitions by Haelixa
Financial Statements - Haelixa
Haelixa Comparisons
Competitors of Haelixa
Haelixa operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
Dental implants and regenerative dentistry products are developed.
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
Frequently Asked Questions about Haelixa
Haelixa was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Haelixa is headquartered in Zurich, Switzerland.
Haelixa is a funded company, having raised a total of $2.49M across 5 funding rounds to date. The company's 1st funding round was a Grant of $730.19K, raised on Jan 09, 2017.
Haelixa was founded in 2015 in Zurich, Switzerland. DNA-based tracers are offered for the energy industry, enabling fluid tracking and monitoring of parameters such as temperature, light, pH, and oxidants in subsurface environments. Encapsulated DNA sequences provide unique identification at parts-per-trillion levels, supporting reservoir characterization and product authentication. Operations focus on exploration, quality control, and liability management within harsh conditions.
Haelixa's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Haelixa offers DNA Marking Technology.
Haelixa has 6 investors. Key investors include Clariant, Zurcher Kantonalbank, European Union, Verve Ventures, and Venture Kick.